Recent advances in understanding steatotic liver disease have revealed overlapping biological processes that may contribute to non-alcoholic fatty liver disease (NAFLD). Join us in this podcast series where your colleagues will take you on a journey to better understand the cardiometabolic basis for metabolic dysfunction-associated steatohepatitis (MASH), formerly known as non-alcoholic steatohepatitis (NASH), which has long been recognized as “the hepatic manifestation of the metabolic syndrome.” In this series, we will explore MASH, including epidemiology, pathophysiology, comorbidities, patients at risk, and HCP perspectives on the patient journey. This series is tailored specifically for healthcare professionals seeking deeper insights into MASH.
Expose MASH [Formerly NASH] is tailored for healthcare professionals seeking to stay at the forefront of liver disease knowledge. This podcast is sponsored by Novo Nordisk and is intended for U.S. clinicians. This podcast is not to be used as medical advice.
All content for Expose MASH [Formerly NASH] is the property of Novo Nordisk and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Recent advances in understanding steatotic liver disease have revealed overlapping biological processes that may contribute to non-alcoholic fatty liver disease (NAFLD). Join us in this podcast series where your colleagues will take you on a journey to better understand the cardiometabolic basis for metabolic dysfunction-associated steatohepatitis (MASH), formerly known as non-alcoholic steatohepatitis (NASH), which has long been recognized as “the hepatic manifestation of the metabolic syndrome.” In this series, we will explore MASH, including epidemiology, pathophysiology, comorbidities, patients at risk, and HCP perspectives on the patient journey. This series is tailored specifically for healthcare professionals seeking deeper insights into MASH.
Expose MASH [Formerly NASH] is tailored for healthcare professionals seeking to stay at the forefront of liver disease knowledge. This podcast is sponsored by Novo Nordisk and is intended for U.S. clinicians. This podcast is not to be used as medical advice.
In this sixth episode of Expose MASH [formerly NASH]—intended for US healthcare professionals only—we share insight on primary fibrosis risk assessment using the FIB-4 index in patients with MASH (metabolic dysfunction-associated steatohepatitis). Our experts explain the importance of noninvasive tests as a useful tool to identify patients at high risk for MASH. Futhermore, they discuss the relevance of using the FIB-4 test in order to facilitate timely intervention for these at-risk patients. This episode is brought to you by Novo Nordisk Inc.
Expose MASH [Formerly NASH]
Recent advances in understanding steatotic liver disease have revealed overlapping biological processes that may contribute to non-alcoholic fatty liver disease (NAFLD). Join us in this podcast series where your colleagues will take you on a journey to better understand the cardiometabolic basis for metabolic dysfunction-associated steatohepatitis (MASH), formerly known as non-alcoholic steatohepatitis (NASH), which has long been recognized as “the hepatic manifestation of the metabolic syndrome.” In this series, we will explore MASH, including epidemiology, pathophysiology, comorbidities, patients at risk, and HCP perspectives on the patient journey. This series is tailored specifically for healthcare professionals seeking deeper insights into MASH.
Expose MASH [Formerly NASH] is tailored for healthcare professionals seeking to stay at the forefront of liver disease knowledge. This podcast is sponsored by Novo Nordisk and is intended for U.S. clinicians. This podcast is not to be used as medical advice.
